AGED Diagnostics develops a blood test utilizing targeted genomic sequencing to diagnose and stage liver disease, including NASH and fibrosis. This noninvasive assessment measures circulating genetic biomarkers to differentiate disease severity from benign conditions. The technology aims to enable earlier patient intervention, improving outcomes and reducing healthcare costs associated with late-stage liver disease.
Funding
Funding not disclosed
Founders
Product
Problem
A significant portion of the population, estimated at 1 in 3 Americans, has liver disease, often remaining unaware until advanced stages. Current diagnostic methods, such as liver biopsy, are invasive and prone to sampling errors, while imaging techniques exhibit low accuracy. This lack of precise, non-invasive early detection leads to poorer patient outcomes and increased healthcare expenditures.
Solution
AGED Diagnostics is developing a highly accurate blood test for liver disease, leveraging genomic sequencing to quantify specific circulating biomarkers. This proprietary technology enables the differentiation of benign liver conditions from advanced stages, including the precise staging of liver fibrosis. By providing an objective, non-invasive diagnostic tool, AGED Diagnostics aims to facilitate earlier detection and intervention, thereby improving patient prognoses and reducing the financial burden on healthcare systems. The platform is designed to assist physicians in patient monitoring programs and offers a more reliable alternative to current diagnostic standards.
Target Audience
The primary target audience includes hepatologists, gastroenterologists, and primary care physicians who manage patients with liver disease, as well as health insurers seeking more accurate and cost-effective diagnostic solutions.
Features
- Targeted genomic sequencing assay to measure specific genetic signatures (biomarkers) in circulation.
- Capability to differentiate between simple steatosis and nonalcoholic steatohepatitis (NASH).
- Ability to identify and stage advanced fibrosis with high accuracy.
- Technology designed to exclude other chronic liver diseases.
- Blood-based diagnostic approach, offering a non-invasive alternative to liver biopsy.